Here, we present a review focusing on three relevant issues related to COVID-19 and its
impact in older adults (60 years and older). SARS-CoV-2 infection starts in the respiratory …

Convalescent plasma (CP) therapy might be effective in patients with haematological
malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 …

Introduction Since COVID-19 patients are often polytreated, monitoring drug–drug
interaction (DDIs) is necessary. We evaluated whether drugs used after the second COVID …

There is an ongoing debate worldwide about the possible benefits of ivermectin for the
treatment and prevention of COVID-19. Some advocacy groups have concluded, based on …

Remdesivir is the first drug approved for treatment of COVID-19 but current evidence for
recommending its use for the treatment of moderate-to-severe disease is still controversial …

Remdesivir (RDV) has demonstrated clinical benefit in hospitalized COronaVIrus Disease
(COVID)-19 patients. The objective of this brief report was to assess a possible correlation …

The purpose of this study was to investigate the clinical application of severe acute
respiratory distress syndrome coronavirus-2 (SARS-CoV-2) specific antibody detection and …

Background: Since the SARS-CoV-2 pandemic emerged, antimicrobial stewardship (AS)
activities need to be diverted into COVID-19 management. Methods: In order to assess the …

The benefits of remdesivir treatment, with or without co-administration of antibiotics such as
azithromycin, are uncertain in COVID-19 pneumonia. The aim of this retrospective single …

Introduction. Research shows the correlation between angiotensin-converting enzyme
(ACE) deletion and insertion (D/I) polymorphism and COVID-19 risk; yet, conclusive …